Multicenter, phase II study of bendamustine in refractory or relapsed T-cell lymphoma: The BENTLY trial.

被引：0

作者：

Gressin, Remy

Damaj, Gandhi Laurent

Bouabdallah, Kamal

Cartron, Guillaume

Choufi, B.

Gyan, Emmanuel

Jaccard, Arnaud

Park, Sophie

De Colella, Jean-Marc Schiano

Voillat, Laurent

Joly, Bertrand

Le Gouill, Steven

Saad, Alain

Sanhes, Laurence

Moles-Moreau, Marie-Pierre

Bubenheim, Michael

Bene, Marie C.

Martin, Antoine

Marolleau, Jean Pierre

Lamy, Thierry

机构：

[1] Univ Hosp Grenoble, Grenoble, France

[2] Ctr Hosp Univ Amiens Sud, Amiens, France

[3] Hop Haut Leveque, Ctr Francois Magendie, Dept Hemagol, Pessac, France

[4] Univ Hosp Montpellier, Montpellier, France

[5] CH Boulogne, Boulogne, France

[6] Univ Hosp Tours, Tours, France

[7] CHU Cochin Port Royal, Paris, France

[8] Inst J Paoli I Calmettes, F-13009 Marseille, France

[9] Hop Chalons Sur Saone, Chalons Sur Saone, France

[10] Ctr Hosp Sud Francilien, Corbeil Essonnes, France

[11] Univ Hosp Nantes, Nantes, France

[12] Hop Beziers, Beziers, France

[13] Hop Perpignan, Perpignan, France

[14] Univ Hosp Angers, Angers, France

[15] Rouen Univ Hosp Charles Nicolle, Dept Biostat, Rouen, France

[16] CHU Brabois, Immunol Lab, Vandoeuvre Les Nancy, France

[17] Nancy Univ, Vandoeuvre Les Nancy, France

[18] Univ Hosp Avicenne, Bobigny, France

[19] CHU Amiens, Amiens, France

[20] CHU Pontchaillou, Rennes, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8026

引用

页数：1

共 50 条

[21] Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
Dang, Nam H.
Pro, Barbara
Hagemeister, Fredrick B.
Samaniego, Felipe
Jones, Dan
Samuels, Barry I.
Rodriguez, Maria A.
McLaughlin, Peter
Tong, Ann T.
Turturro, Francesco
Walker, Pamela L.
Fayad, Luis
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (03) : 439 - 447
[22] Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
Zinzani, Pier Luigi
Musuraca, Gerardo
Tani, Monica
Stefoni, Vittorio
Marchi, Enrica
Fina, Mariapaola
Pellegrini, Cinzia
Alinari, Lapo
Derenzini, Enrico
de Vivo, Antonio
Sabattini, Elena
Pileri, Stefano
Baccarani, Michele
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) : 4293 - 4297
[23] Phase II study of pentostatin in relapsed T-cell lymphoma
D'Orazio, AI
Fisher, MD
CLINICAL LYMPHOMA, 2002, 2 (04): : 206 - 207
[24] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Kim, W. S.
Ando, K.
Niitsu, N.
Ogura, M.
Takahashi, N.
Uike, N.
Eom, H. Seok
Chae, Y. S.
Tobinai, K.
Terauchi, T.
Tateishi, U.
Tatsumi, M.
Suh, C.
ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
[25] Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study
Nicolay, Jan P.
Melchers, Susanne
Albrecht, Jana D.
Assaf, Chalid
Dippel, Edgar
Stadler, Rudolf
Wehkamp, Ulrike
Wobser, Marion
Zhao, Jing
Burghaus, Ina
Schneider, Sven
Guelow, Karsten
Goerdt, Sergij
Schuerch, Christian M.
Utikal, Jochen S.
Krammer, Peter H.
BLOOD, 2023, 142 (09) : 794 - 805
[26] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ohmachi, Ken
Niitsu, Nozomi
Uchida, Toshiki
Kim, Seok Jin
Ando, Kiyoshi
Takahashi, Naoki
Takahashi, Naoto
Uike, Naokuni
Eom, Hyeon Seok
Chae, Yee Soo
Terauchi, Takashi
Tateishi, Ukihide
Tatsumi, Mitsuaki
Kim, Won Seog
Tobinai, Kensei
Suh, Cheolwon
Ogura, Michinori
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
[27] Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"
Tournilhac, Olivier
Lecolant, Solene
Hacini, Maya
Bouabdallah, Krimo
Bailly, Sebastien
Laribi, Kamel
Belmondo, Thibaut
Maerevoet, Marie
Ysebaert, Loic
Guidez, Stephanie
Le Gouill, Steven
Bonnet, Christophe
Andre, Marc
Dupuis, Jehan
Thieblemont, Catherine
Bachy, Emmanuel
Daguindau, Nicolas
Morschhauser, Franck
Tricot, Sabine
Feugier, Pierre
Banos, Anne
Lamy, Thierry
Chauchet, Adrien
Gyan, Emmanuel
Cartron, Guillaume
Farhat, Hassan
Camus, Vincent
Drenou, Bernard
Zerazhi, Hacene
Sibon, David
Nicolas-Virelizier, Emmanuelle
Delette, Caroline
Snauwaert, Sylvia
Straetmans, Nicole
Delarue, Richard
Parrens, Marie
Griolet, Samuel
Gaulard, Philippe
Delfau-Larue, Marie-Helene
De Leval, Laurence
Damaj, Gandhi Laurent
BLOOD, 2022, 140 : 2302 - 2305
[28] PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
O'Connor, O.
Pro, B.
Pinter-Brown, L.
Popplewell, L.
Bartlett, N.
Lechowicz, M.
Savage, K.
Coiffier, B.
Saunders, M.
Horwitz, S.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[29] A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular Lymphoma
Kaleka, Guneet
Moskoff, Benjamin
Zafar, Aneeqa
Esteghamat, Naseem S.
Abedi, Mehrdad
Socola, Francisco Andres
Hoeg, Rasmus T.
Tuscano, Joseph M.
BLOOD, 2024, 144 : 6318 - 6319
[30] Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study
R Sakai
K Ohmachi
F Sano
R Watanabe
H Takahashi
H Takasaki
M Tanaka
Y Hattori
H Kimura
M Takimoto
T Tachibana
E Tanaka
Y Ishii
Y Ishiyama
M Hagihara
K Miyazaki
K Yamamoto
N Tomita
K Ando
Annals of Hematology, 2019, 98 : 2131 - 2138

← 1 2 3 4 5 →